UOC
BBIO icon

UBS O'Connor’s BridgeBio Pharma BBIO Stock Holding History

UBS O'Connor’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,771
Closed -$595K – 300
2025
Q2 		$595K Sell
13,771
-11,721
-46% -$426K 0.02% 262
2025
Q1 		$881K Sell
25,492
-35,626
-58% -$1.2M 0.02% 198
2024
Q4 		$1.68M Buy
61,118
+2,522
+4% +$65.2K 0.04% 178
2024
Q3 		$1.49M Buy
58,596
+22,096
+61% +$580K 0.04% 221
2024
Q2 		$925K Buy
+36,500
New +$998K 0.03% 307
2024
Q1 		– Sell
-14,318
Closed -$578K – 525
2023
Q4 		$578K Sell
14,318
-42,982
-75% -$1.29M 0.02% 335
2023
Q3 		$1.51M Buy
+57,300
New +$1.63M 0.03% 282

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return